AR074358A1 - Derivados de pirazina como inhibidores de la fosfodiesterasa 10 - Google Patents
Derivados de pirazina como inhibidores de la fosfodiesterasa 10Info
- Publication number
- AR074358A1 AR074358A1 ARP090104436A ARP090104436A AR074358A1 AR 074358 A1 AR074358 A1 AR 074358A1 AR P090104436 A ARP090104436 A AR P090104436A AR P090104436 A ARP090104436 A AR P090104436A AR 074358 A1 AR074358 A1 AR 074358A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkc1
- nrara
- 6nrara
- 6ora
- ora
- Prior art date
Links
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 title 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 10
- 229910052717 sulfur Inorganic materials 0.000 abstract 7
- 229910052760 oxygen Inorganic materials 0.000 abstract 6
- 125000004429 atom Chemical group 0.000 abstract 5
- 229910052799 carbon Inorganic materials 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000002619 bicyclic group Chemical group 0.000 abstract 3
- 125000002950 monocyclic group Chemical group 0.000 abstract 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 abstract 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 1
- 229910003827 NRaRb Inorganic materials 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- MPVDXIMFBOLMNW-UHFFFAOYSA-N chembl1615565 Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1N=NC1=CC=CC=C1 MPVDXIMFBOLMNW-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003216 pyrazines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11456708P | 2008-11-14 | 2008-11-14 | |
| US16621209P | 2009-04-02 | 2009-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074358A1 true AR074358A1 (es) | 2011-01-12 |
Family
ID=41478512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104436A AR074358A1 (es) | 2008-11-14 | 2009-11-16 | Derivados de pirazina como inhibidores de la fosfodiesterasa 10 |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US8053438B2 (OSRAM) |
| EP (1) | EP2364308B1 (OSRAM) |
| JP (1) | JP5746972B2 (OSRAM) |
| KR (1) | KR20110083746A (OSRAM) |
| CN (1) | CN102300860B (OSRAM) |
| AR (1) | AR074358A1 (OSRAM) |
| AU (1) | AU2009313768B2 (OSRAM) |
| BR (1) | BRPI0922095A2 (OSRAM) |
| CA (1) | CA2742993C (OSRAM) |
| CL (1) | CL2011001094A1 (OSRAM) |
| CO (1) | CO6382157A2 (OSRAM) |
| CR (1) | CR20110326A (OSRAM) |
| CY (1) | CY1113680T1 (OSRAM) |
| DK (1) | DK2364308T3 (OSRAM) |
| EA (1) | EA019206B1 (OSRAM) |
| ES (1) | ES2397218T3 (OSRAM) |
| HR (1) | HRP20130054T1 (OSRAM) |
| IL (1) | IL212687A0 (OSRAM) |
| MA (1) | MA32889B1 (OSRAM) |
| MX (1) | MX2011005100A (OSRAM) |
| NZ (1) | NZ592508A (OSRAM) |
| PE (1) | PE20110581A1 (OSRAM) |
| PL (1) | PL2364308T3 (OSRAM) |
| PT (1) | PT2364308E (OSRAM) |
| RS (1) | RS52598B (OSRAM) |
| SI (1) | SI2364308T1 (OSRAM) |
| SM (1) | SMT201200061B (OSRAM) |
| TN (1) | TN2011000221A1 (OSRAM) |
| TW (1) | TWI396689B (OSRAM) |
| WO (1) | WO2010057121A1 (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| WO2010077992A1 (en) * | 2008-12-17 | 2010-07-08 | Amgen Inc. | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors |
| EP3006031A1 (en) | 2009-02-05 | 2016-04-13 | Takeda Pharmaceutical Company Limited | Pyridazinone compounds |
| CA2760837C (en) * | 2009-05-12 | 2018-04-03 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof |
| JP5739415B2 (ja) | 2009-05-12 | 2015-06-24 | ブリストル−マイヤーズ スクウィブ カンパニー | （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用 |
| JP5780528B2 (ja) | 2010-02-19 | 2015-09-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 三環式ピリジン誘導体、このような化合物を含有する医薬、それらの使用、およびそれらの調製方法 |
| UY33463A (es) | 2010-06-24 | 2012-01-31 | Takeda Pharmaceutical | Compuestos heterocíclicos fusionados |
| EP2602255B1 (en) | 2010-08-04 | 2017-04-26 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring compound |
| JP5760085B2 (ja) * | 2010-08-04 | 2015-08-05 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| WO2012020780A1 (ja) | 2010-08-10 | 2012-02-16 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| KR20180099933A (ko) | 2010-11-19 | 2018-09-05 | 리간드 파마슈티칼스 인코포레이티드 | 복소환 아민 및 이의 용도 |
| US8765760B2 (en) | 2011-01-11 | 2014-07-01 | Sunovion Pharmaceuticals, Inc. | [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases |
| EP2687529B1 (en) | 2011-03-16 | 2016-07-13 | Takeda Pharmaceutical Company Limited | Condensed heterocyclic compound |
| TWI570122B (zh) | 2011-06-22 | 2017-02-11 | 武田藥品工業股份有限公司 | 稠合雜環化合物之結晶 |
| CA2922849A1 (en) * | 2012-08-31 | 2014-03-06 | Ixchel Pharma, Llc | Agents useful for treating obesity, diabetes and related disorders |
| CN102911135B (zh) * | 2012-10-18 | 2016-01-13 | 内蒙古工业大学 | 2-巯基苯并噻唑类衍生物的合成方法 |
| PE20151301A1 (es) | 2013-02-05 | 2015-09-16 | Purdue Pharma Lp | Formulaciones farmaceuticas resistentes a la manipulacion indebida |
| EP2975037A4 (en) | 2013-03-15 | 2016-08-10 | Daiichi Sankyo Co Ltd | benzothiophene derivative |
| US10039764B2 (en) | 2013-07-12 | 2018-08-07 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression |
| RU2016110852A (ru) | 2013-09-27 | 2017-10-30 | Нимбус Айрис, Инк. | Ингибиторы irak и их применения |
| US9657015B2 (en) | 2014-07-31 | 2017-05-23 | Boehringer Ingelheim International Gmbh | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity |
| CN104649882A (zh) * | 2015-02-11 | 2015-05-27 | 南通恒盛精细化工有限公司 | 一种磷酸二酯酶抑制剂的中间体制备工艺 |
| US10807983B2 (en) | 2015-03-16 | 2020-10-20 | Ligand Pharmaceuticals, Inc. | Imidazo-fused heterocycles and uses thereof |
| US10647675B2 (en) * | 2015-09-18 | 2020-05-12 | Kaken Pharmaceutical Co., Ltd. | Biaryl derivative and medicine containing same |
| CN112979661B (zh) * | 2018-01-19 | 2022-05-17 | 苏州信诺维医药科技股份有限公司 | 杂环化合物、制备方法及其在医药上的应用 |
| CN109020977B (zh) * | 2018-10-26 | 2020-11-13 | 安庆奇创药业有限公司 | 一种Acalabrutinib的制备方法 |
| JP2023553699A (ja) | 2020-12-17 | 2023-12-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ヘテロ芳香族イソチオシアネート類 |
| CN113929598A (zh) * | 2021-11-24 | 2022-01-14 | 上海吉奉生物科技有限公司 | 一种（s）-2-叔丁氧羰基氨基-3-（4,4-二氟环己基）丙酸的合成方法 |
| JP2025515208A (ja) * | 2022-05-09 | 2025-05-13 | ティーワイケー メディシンズ インコーポレーテッド | 多環式化合物およびその使用 |
| CN115894181A (zh) * | 2022-09-30 | 2023-04-04 | 渭南高新区海泰新型电子材料有限责任公司 | 一种环己烯基环己基二氟苯类液晶化合物的合成方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4198417A (en) | 1979-01-10 | 1980-04-15 | American Hoechst Corporation | Phenoxyphenylpiperidines |
| SI1635828T1 (sl) | 2003-04-04 | 2008-08-31 | Lundbeck & Co As H | Derivati 4-(2-feniloksifenil)-piperidina ali-1,2,3,6-tetrahidropiridina kot inhibitorji ponovnega privzema serotonina |
| DE10337942A1 (de) | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
| DE10344223A1 (de) | 2003-09-24 | 2005-04-21 | Merck Patent Gmbh | 1,3-Benzoxazolylderivate als Kinase-Inhibitoren |
| DE10349587A1 (de) | 2003-10-24 | 2005-05-25 | Merck Patent Gmbh | Benzimidazolylderivate |
| US7470712B2 (en) | 2004-01-21 | 2008-12-30 | Bristol-Myers Squibb Company | Amino-benzazoles as P2Y1 receptor inhibitors |
| JP4584990B2 (ja) * | 2004-05-18 | 2010-11-24 | シェーリング コーポレイション | Ｐｄｅ４インヒビターとして有用な置換２−キノリル−オキサゾール |
| WO2005120514A1 (en) * | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| US20060183763A1 (en) * | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| DE102005016634A1 (de) | 2005-04-12 | 2006-10-19 | Merck Patent Gmbh | Neuartige Aza-Hetercyclen als Kinase-Inhibitoren |
| BRPI0614472A2 (pt) | 2005-08-02 | 2011-03-29 | Irm Llc | compostos e composições como inibidores de proteìna quinase |
| US20070265256A1 (en) * | 2006-02-21 | 2007-11-15 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| US7868177B2 (en) | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
| US20090176829A1 (en) * | 2006-05-02 | 2009-07-09 | Pfizer Inc | Bicyclic heteroaryl compounds as pde10 inhibitors |
| US20080090834A1 (en) * | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| WO2008057280A1 (en) | 2006-10-27 | 2008-05-15 | Amgen Inc. | Multi-cyclic compounds and methods of use |
| SI2125786T1 (sl) * | 2006-12-21 | 2011-05-31 | Pfizer Prod Inc | Sukcinat sol 2-((4-(1-metil-4-(piridin-4-il)-1H-pirazol-3-il)fenoksi)metil)kinolina |
| JP2011500778A (ja) | 2007-10-25 | 2011-01-06 | アストラゼネカ・アクチエボラーグ | ピリジン及びピラジン誘導体−０８３ |
| WO2009081259A1 (en) | 2007-12-21 | 2009-07-02 | Pfizer Inc. | Phenoxy-pyridyl derivatives |
| MX2010013876A (es) | 2008-06-20 | 2011-03-04 | Metabolex Inc | Agonistas de arilo grpr119 y sus usos . |
-
2009
- 2009-11-13 TW TW098138718A patent/TWI396689B/zh not_active IP Right Cessation
- 2009-11-16 EA EA201100748A patent/EA019206B1/ru not_active IP Right Cessation
- 2009-11-16 CN CN200980154871.6A patent/CN102300860B/zh not_active Expired - Fee Related
- 2009-11-16 RS RS20120569A patent/RS52598B/sr unknown
- 2009-11-16 EP EP09752705A patent/EP2364308B1/en active Active
- 2009-11-16 NZ NZ592508A patent/NZ592508A/xx not_active IP Right Cessation
- 2009-11-16 PL PL09752705T patent/PL2364308T3/pl unknown
- 2009-11-16 AU AU2009313768A patent/AU2009313768B2/en not_active Ceased
- 2009-11-16 HR HRP20130054AT patent/HRP20130054T1/hr unknown
- 2009-11-16 BR BRPI0922095A patent/BRPI0922095A2/pt not_active IP Right Cessation
- 2009-11-16 KR KR1020117013506A patent/KR20110083746A/ko not_active Withdrawn
- 2009-11-16 US US12/619,574 patent/US8053438B2/en not_active Expired - Fee Related
- 2009-11-16 CA CA2742993A patent/CA2742993C/en not_active Expired - Fee Related
- 2009-11-16 ES ES09752705T patent/ES2397218T3/es active Active
- 2009-11-16 SI SI200930429T patent/SI2364308T1/sl unknown
- 2009-11-16 MX MX2011005100A patent/MX2011005100A/es active IP Right Grant
- 2009-11-16 AR ARP090104436A patent/AR074358A1/es not_active Application Discontinuation
- 2009-11-16 PT PT97527055T patent/PT2364308E/pt unknown
- 2009-11-16 JP JP2011536567A patent/JP5746972B2/ja not_active Expired - Fee Related
- 2009-11-16 WO PCT/US2009/064637 patent/WO2010057121A1/en not_active Ceased
- 2009-11-16 PE PE2011001035A patent/PE20110581A1/es not_active Application Discontinuation
- 2009-11-16 DK DK09752705.5T patent/DK2364308T3/da active
-
2011
- 2011-03-07 US US13/042,421 patent/US8247418B2/en not_active Expired - Fee Related
- 2011-03-07 US US13/042,410 patent/US8329700B2/en not_active Expired - Fee Related
- 2011-05-04 IL IL212687A patent/IL212687A0/en unknown
- 2011-05-05 TN TN2011000221A patent/TN2011000221A1/fr unknown
- 2011-05-13 CL CL2011001094A patent/CL2011001094A1/es unknown
- 2011-06-10 MA MA33928A patent/MA32889B1/fr unknown
- 2011-06-14 CR CR20110326A patent/CR20110326A/es not_active Application Discontinuation
- 2011-06-14 CO CO11073978A patent/CO6382157A2/es not_active Application Discontinuation
-
2012
- 2012-06-22 US US13/531,453 patent/US20120277209A1/en not_active Abandoned
- 2012-12-19 SM SM201200061T patent/SMT201200061B/it unknown
- 2012-12-21 CY CY20121101246T patent/CY1113680T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074358A1 (es) | Derivados de pirazina como inhibidores de la fosfodiesterasa 10 | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| AR074775A1 (es) | Compuestos aminopiridina y carboxipiridina como inhibidores de fosfodiesterasa 10 | |
| AR070221A1 (es) | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. | |
| AR074966A1 (es) | Compuestos amino-heterociclicos | |
| AR074343A1 (es) | Derivados de piridina y pirimidina como inhibidores de la fosfodiesterasa 10 | |
| AR065876A1 (es) | Compuestos activos para 11 beta -hsd1 | |
| AR076754A1 (es) | Dihidropirimidinas y proceso de obtencion de las mismas | |
| AR064299A1 (es) | Derivados de sulfonil-fenil-2h- [1,2,4] oxadiazol-5-ona procesos para su preparacion y su uso como agentes farmaceuticos | |
| UY33245A (es) | Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas | |
| AR075243A1 (es) | Derivados del 1-fenil-2-piridinil alquil alcohol como inhibidores de fosfodiesterasa | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| NI201300072A (es) | Derivados de heteroarilo como moduladores nachr alfa 7 | |
| AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| ECSP099728A (es) | Compuestos amino-heterocíclicos | |
| AR076486A1 (es) | Inhibidores de fosfoinositida 3 kinasa y composiciones farmaceuticas que los contienen. | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR081369A1 (es) | Compuestos de 2-5-6-7-tetrahidro-(1,4) oxazepin-3-ilamina o 2,3,6,7-tetrahidro-(1,4) oxazepin-5-ilamina, sus procesos de obtencion y composiciones farmaceuticas que los contienen | |
| CO6260069A2 (es) | Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa | |
| AR086100A1 (es) | Compuestos de cromenona y composiciones farmaceuticas que los contienen | |
| AR076236A1 (es) | Compuestos organicos y sus usos | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| AR063454A1 (es) | Derivados acetamida de diazepan como inhibidores selectivos de 11 beta - hsd1. procesos de obtencion y composiciones farmaceuticas. | |
| AR087915A1 (es) | N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1 | |
| AR078756A1 (es) | Moduladores alostericos positivos (map) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |